Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6563237 | 0.83 | POLB (0.41) | TRPV1KMT2ALMNAPOLB | |
| SCHEMBL13194426 | 0.81 | ADRA2B (0.49) | TRPV1KMT2ALMNAEPHX2SETDB1 | |
| SCHEMBL14831186 | 0.80 | ALDH1A1 (0.46) | TRPV1KMT2ALMNARECQLEPHX2 | |
| SCHEMBL24632660 | 0.79 | TRPV1 (0.44) | TRPV1KMT2ALMNAEPHX2SETDB1 | |
| SCHEMBL13172655 | 0.78 | P2RX7 (0.45) | TRPV1LMNAEPHX2 | |
| SCHEMBL1695325 | 0.76 | CSNK2A1 (0.45) | GAA | |
| SCHEMBL5314524 | 0.76 | KMT2A (0.59) | KMT2ARECQLMEN1KDM4EPOLB | |
| SCHEMBL21267602 | 0.75 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL30025354 | 0.75 | EPHX2 (0.47) | TRPV1KMT2ARECQLEPHX2KDM4E | |
| SCHEMBL1659054 | 0.74 | TRPV1 (0.52) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760836-A1 | AMINE SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8765733-B2 | Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765733-B2 | Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| WO-2013045451-A1 | AMINE SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079320-A1 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079320-A1 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079320-A1 | Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | TRPV1, TRPA1, TRPV3 | TRPV1 1/4885KMT2A 2872/4885LMNA 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.